BOSTON--(BUSINESS WIRE)--A new paper published today in Cell Reports Medicine suggests that weight loss resulting from Gelesis’ superabsorbent hydrogel treatment is not only a result of its space-occupying properties; the mechanical composition and structure of the material may have notable benefits for gut and metabolic health..

BOSTON-（BUSINESS WIRE）-今天在Cell Reports Medicine上發(fā)表的一篇新論文表明，Gelesis的超吸收性水凝膠處理導(dǎo)致的體重減輕不僅是其占位特性的結(jié)果；材料的機械組成和結(jié)構(gòu)可能對腸道和代謝健康具有顯著益處。。

The continued rise in obesity and type 2 diabetes has led to the increasing prevalence of fatty liver disease worldwide and highlights the urgent need for therapies that can address the problem. Diets rich in fat, sugars, and ultra-processed foods are a contributor to rising obesity rates. These high fat/high carb diets have profound negative impacts on the host gut barrier function and microbial structure.

肥胖和2型糖尿病的持續(xù)增加導(dǎo)致全世界脂肪肝疾病的患病率增加，并強調(diào)迫切需要能夠解決該問題的治療方法。富含脂肪，糖和超加工食品的飲食是導(dǎo)致肥胖率上升的原因。這些高脂肪/高碳水化合物飲食對宿主腸道屏障功能和微生物結(jié)構(gòu)具有深遠的負面影響。

This in turn has a detrimental effect and can lead to increased gut permeability and higher instances of metabolic disorders like obesity, diabetes, and fatty liver..

這反過來又會產(chǎn)生不利影響，并可能導(dǎo)致腸道通透性增加和肥胖，糖尿病和脂肪肝等代謝紊亂的發(fā)生率增加。。

The reported studies examined both the efficacy and mechanism of action of Gelesis’ oral superabsorbent hydrogels (OSH) in preclinical models of diet-induced obesity, metabolic syndrome, and NASH. The Gelesis OSH consistently resulted in weight loss, improved insulin sensitivity, and prevented the progression of NAFLD..

報道的研究檢查了Gelesis口服超吸收性水凝膠（OSH）在飲食誘導(dǎo)的肥胖，代謝綜合征和NASH的臨床前模型中的功效和作用機制。Gelesis OSH始終如一地導(dǎo)致體重減輕，改善胰島素敏感性，并阻止NAFLD的進展。。

Notably, the hydrogel induced endogenous GLP-1 and rapid, unique, and consistent changes in the gut microbiota, specifically fostering the growth of Akkermansia muciniphila, which is thought to be a beneficial microbe for metabolic disorders. Through comparison with supplement fiber (inulin, psyllium and hydrogels with different mechanical properties) it demonstrated that the physical structure of the hydrogel had the unique capability to boost Akkermansia growth.

值得注意的是，水凝膠誘導(dǎo)內(nèi)源性GLP-1和腸道微生物群的快速，獨特和一致的變化，特別是促進Akkermansia muciniphila的生長，其被認為是代謝紊亂的有益微生物。通過與補充纖維（菊粉，車前子和具有不同機械性能的水凝膠）的比較，證明水凝膠的物理結(jié)構(gòu)具有促進Akkermansia生長的獨特能力。

The study also demonstrated that the beneficial metabolic effects were independent of the weight loss effect..

該研究還表明，有益的代謝作用與體重減輕作用無關(guān)。。

“It was exciting to see how specific structural and physical properties are important for achieving the therapeutic effect on the gut microbiota, and how hydrogel-dependent preservation of the gut barrier properties is improving insulin sensitivity, promoting liver health and inducing weight loss,” said Maria Rescigno, PhD, professor at Humanitas University, group leader at Humanitas Research Hospital in Milan and senior author of the paper.

“令人興奮的是，看看具體的結(jié)構(gòu)和物理特性對于實現(xiàn)對腸道微生物群的治療效果是多么重要，以及水凝膠依賴性保存腸道屏障特性如何改善胰島素敏感性，促進肝臟健康和誘導(dǎo)體重減輕，”人文大學(xué)教授Maria Rescigno博士說，米蘭Humanitas研究醫(yī)院組長和該論文的高級作者。

“Our work shows the potential of oral superabsorbent hydrogels to be an effective and non-invasive therapeutic tool in the long-term treatment of obesity and metabolic disorders.”.

“我們的工作表明口服超吸收性水凝膠有可能成為長期治療肥胖和代謝紊亂的有效和非侵入性治療工具。”。

Read the full paper in Cell Reports Medicine here.

在這里閱讀Cell Reports Medicine的全文。

Gelesis Holdings Inc. (“Gelesis”) is a consumer-centered biotherapeutics company and the maker of Plenity?, which is inspired by nature and FDA cleared to aid in weight management. Our first-of-their-kind non-systemic superabsorbent hydrogels are made entirely from naturally derived building blocks.

Gelesis Holdings Inc.（“Gelesis”）是一家以消費者為中心的生物治療公司，也是Plenity?的制造商，該公司受到nature和FDA的啟發(fā)，可以幫助進行體重管理。我們的第一種非系統(tǒng)性超吸收性水凝膠完全由天然衍生的結(jié)構(gòu)單元制成。

They are inspired by the composition and mechanical properties of raw vegetables, taken by capsule, and act locally in the digestive system, so people feel satisfied with smaller portions. Our portfolio includes Plenity? and potential therapies in development for patients with Type 2 Diabetes, Non-alcoholic Fatty Liver Disease (NAFLD)/Non-alcoholic Steatohepatitis (NASH), and Functional Constipation.

它們受到生蔬菜的成分和機械性能的啟發(fā)，由膠囊攝取，并在消化系統(tǒng)中局部起作用，因此人們對較小的部分感到滿意。我們的產(chǎn)品組合包括針對2型糖尿病，非酒精性脂肪性肝?。∟AFLD）/非酒精性脂肪性肝炎（NASH）和功能性便秘患者開發(fā)的Plenity?和潛在療法。

For more information, visit gelesis.com, or connect with us on X, formerly known as Twitter: @GelesisInc..

欲了解更多信息，請訪問gelesis.com，或在X（以前稱為Twitter:@GelesisInc。）上與我們聯(lián)系。。

Plenity? is indicated to aid weight management in adults with excess weight or obesity, a Body Mass Index (BMI) of 25–40 kg/m2, when used in conjunction with diet and exercise.

當(dāng)與飲食和運動結(jié)合使用時，Plenity?有助于超重或肥胖成年人的體重管理，體重指數(shù)（BMI）為25-40 kg/m2。

Important Safety Information about Plenity

關(guān)于充分性的重要安全信息

Patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide should not take Plenity.

懷孕或?qū)w維素，檸檬酸，富馬酸硬脂酸鈉，明膠或二氧化鈦過敏的患者不應(yīng)服用豐滿的藥物。

To avoid impact on the absorption of medications:

避免影響藥物的吸收：

For all medications that should be taken with food, take them after starting a meal.

對于所有應(yīng)該與食物一起服用的藥物，在開始用餐后服用。

For all medications that should be taken without food (on an empty stomach), continue taking on an empty stomach or as recommended by your physician.

對于所有應(yīng)該在沒有食物的情況下服用的藥物（空腹），繼續(xù)空腹或按照醫(yī)生的建議服用。

The overall incidence of side effects with Plenity was no different than placebo. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence.

充分副作用的總發(fā)生率與安慰劑無差異。最常見的副作用是腹瀉，腹部擴張，排便不頻繁和腸胃氣脹。

Contact a doctor right away if problems occur. If you have a severe allergic reaction, severe stomach pain, or severe diarrhea, stop using Plenity until you can speak to your doctor.

如果出現(xiàn)問題，請立即聯(lián)系醫(yī)生。如果您有嚴重的過敏反應(yīng)，嚴重的胃痛或嚴重的腹瀉，請停止使用Plenuity，直到您可以與醫(yī)生交談。

Rx Only. For the safe and proper use of Plenity or more information, talk to a healthcare professional, read the Patient Instructions for Use, or call 1-844-PLENITY.

僅限Rx。為了安全和正確使用完整性或更多信息，請與醫(yī)療保健專業(yè)人員交談，閱讀患者使用說明，或致電1-844-Plenity。

Forward-Looking Statements

前瞻性聲明

Certain statements, estimates, targets and projections in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws. The words “anticipate,” “believe,” continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.

本新聞稿中的某些陳述，估計，目標(biāo)和預(yù)測可能構(gòu)成聯(lián)邦證券法含義內(nèi)的“前瞻性陳述”?！邦A(yù)期”，“相信”，“繼續(xù)”，“可以”，“估計”，“期望”，“打算”，“可以”，“可能”，“計劃”，“可能”，“潛力”，“預(yù)測”，“項目”，“應(yīng)該”，“努力”，“將會”等詞語可以識別前瞻性陳述，但缺少這些詞語并不意味著該陳述不是前瞻性的。

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Gelesis’ or its management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including those relating to Gelesis’ expected operating and financial performance and market opportunities.

前瞻性陳述是基于當(dāng)前預(yù)期和假設(shè)的關(guān)于未來事件的預(yù)測，預(yù)測和其他陳述，因此受到風(fēng)險和不確定性的影響。前瞻性陳述包括但不限于關(guān)于Gelesis'或其管理團隊對未來的期望，希望，信念，意圖或策略的陳述，包括與Gelesis的預(yù)期運營和財務(wù)績效以及市場機會相關(guān)的陳述。

In addition, any statements that refer to guidance, projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Gelesis assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

此外，任何涉及未來事件或情況的指導(dǎo)，預(yù)測，預(yù)測或其他特征（包括任何基本假設(shè)）的陳述都是前瞻性陳述。前瞻性陳述僅在其作出之日才發(fā)表。警告讀者不要過分依賴前瞻性陳述，Gelesis不承擔(dān)任何義務(wù)，也不打算更新或修改這些前瞻性陳述，無論是由于新信息，未來事件還是其他原因。

Gelesis gives no assurance that any expectations set forth in this press release will be achieved. Various risks and uncertainties (some of which are beyond Gelesis’ control) or other factors could cause actual future results, performance or events to.

Gelesis不能保證本新聞稿中提出的任何期望都會實現(xiàn)。各種風(fēng)險和不確定性（其中一些超出了Gelesis的控制范圍）或其他因素可能導(dǎo)致實際的未來結(jié)果，表現(xiàn)或事件。

相關(guān)知識

「Cell子刊最新研究」可食用水凝膠在減重中的應(yīng)用可改善代謝疾病
今日Cell：國內(nèi)團隊發(fā)現(xiàn)新腸道激素，連起腸肝軸膽固醇代謝調(diào)控
健康的減肥藥真的要來了？降體重、消炎癥，還能改善代謝健康，或成為減肥者福音！
Protein & Cell：腸道菌群及其代謝物在代謝性疾病中的作用
Cell子刊：人到中年有胖有瘦，揭開代謝在其中的責(zé)任
腸菌移植（FMT）治療非酒精性脂肪肝研究進展
Cell論文揭示精氨酸驅(qū)動代謝重編程促進肝癌生長
腸道菌群及其代謝物在抑郁癥發(fā)生和治療中的作用
去爾濱一趟，還有意外收獲？Cell子刊：2小時寒冷暴露促進心血管代謝健康
Cell子刊：生酮飲食促進健康衰老，改善記憶力

網(wǎng)址: Cell Reports Medicine出版物展示了Gelesis的口服治療水凝膠如何在臨床前研究中通過靶向腸肝軸促進減肥和代謝健康 http://www.u1s5d6.cn/newsview886261.html